Table 4.
Results of European meta-analysis for hospitalization risk
| Meta-all | Meta-males | Meta-females | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SNP | chr:position | EA | NEA | beta | SE | P-value | beta | SE | P-value | beta | SE | P-value | Nearest gene |
| rs115679256 | 3:45587795 | G | A | 0.37 | 0.06 | 1.3E−08 | 0.41 | 0.08 | 5.6E−07 | 0.36 | 0.09 | 1.6E−04 | LIMD1 |
| rs13078854 | 3:45820440 | G | A | 0.53 | 0.04 | 6.7E−34 | 0.64 | 0.05 | 2.7E−33 | 0.38 | 0.06 | 1.0E−09 | LZTFL1 |
| rs41289622 | 3:45973053 | T | G | 0.36 | 0.04 | 3.6E−21 | 0.44 | 0.05 | 3.4E−20 | 0.27 | 0.05 | 7.2E−07 | FYCO1 |
| rs115102354 | 3:46180545 | A | G | 0.40 | 0.06 | 8.9E−12 | 0.48 | 0.07 | 6.8E−11 | 0.26 | 0.08 | 1.8E−03 | XCR1 |
| rs61882275 | 11:34482745 | G | A | −0.12 | 0.02 | 1.0E−06 | −0.17 | 0.03 | 4.1E−08 | −0.08 | 0.03 | 1.3E−02 | ELF5 |
| rs4767028 | 12:112921383 | A | G | −0.16 | 0.02 | 1.6E−10 | −0.19 | 0.03 | 2.5E−09 | −0.11 | 0.04 | 8.7E−04 | OAS1 |
| rs12609134 | 19:35687796 | G | A | −0.19 | 0.03 | 2.3E−08 | −0.22 | 0.04 | 9.5E−08 | −0.13 | 0.05 | 6.0E−03 | UPK1A/ZBTB32 |
| rs17860169 | 21:33240996 | A | G | 0.18 | 0.03 | 3.9E−12 | 0.21 | 0.03 | 1.6E−10 | 0.15 | 0.04 | 2.9E−05 | IFNAR2 |
Note: Summary statistics of both phases (SCOURGE and CNIO) were meta-analysed with four additional sex-disaggregated European studies from the COVID-19 HGI consortium. EA, effect allele; NEA, non-effect allele; beta, effect coefficient; SE, standard error.